Plain-English translation of NCT07086638 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new approach to treating severe radiation dermatitis—painful skin damage that occurs as a side effect of cancer radiotherapy. The treatment uses Prussian blue, an FDA-approved compound that is specially formulated into a nanozyme, combined with near-infrared light therapy. When applied together, this medication is designed to reduce harmful oxidative stress in damaged skin and generate gentle heat to speed up healing.
Severe radiation-related skin damage is a common and difficult problem for head and neck cancer patients undergoing radiotherapy, and there are currently very few effective treatments available. This trial is exploring whether this new combination approach can offer patients faster healing and better quality of life.
You likely qualify if…
You likely don't qualify if…
If you qualify, researchers will apply the treatment directly to the affected skin area and then expose it to near-infrared light, which activates the medication and generates mild warmth to promote healing. The exact schedule of visits and treatments would be discussed with the study team. The goal is to safely reduce your skin damage and improve your comfort as quickly as possible.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China
Sponsor
West China Hospital
Enrollment target
~5 participants
Started
July 2025
Primary completion
May 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xingchen Peng
Sichuan University West China Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.